<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="https://m2.mtmt.hu/xsl/gui3.xsl" ?>
<myciteResult>
  <serverUrl>https://m2.mtmt.hu/</serverUrl>
  <labelLang>eng</labelLang>
  <responseDate>2026-06-13 03:10</responseDate>
  <content>
    <publication>
      <otype>JournalArticle</otype>
      <mtid>33044489</mtid>
      <status>APPROVED</status>
      <published>true</published>
      <comment>Institute for Clinical Diabetology, German Diabetes Centre, Leibniz Centre for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, Germany            
            Department of Endocrinology and Diabetology, Medical Faculty, University Hospital Düsseldorf, Düsseldorf, Germany            
            German Centre for Diabetes Research, Partner Düsseldorf, München-Neuherberg, Germany            
            Department of Diabetes, Monash University, Melbourne, VIC, Australia            
            Export Date: 9 August 2022            
            Correspondence Address: Jandeleit-Dahm, K.; Department of Diabetes, Australia; email: Karin.jandeleit-dahm@monash.edu</comment>
      <unhandledTickets>0</unhandledTickets>
      <deleted>false</deleted>
      <lastRefresh>2025-11-18T10:45:21.601+0000</lastRefresh>
      <lastModified>2024-12-12T12:51:33.302+0000</lastModified>
      <created>2022-08-09T14:02:21.423+0000</created>
      <creator>
        <snippet>true</snippet>
        <mtid>10031137</mtid>
        <familyName>Sonnevend</familyName>
        <givenName>Kinga</givenName>
        <link>/api/admin/10031137</link>
        <otype>Admin</otype>
        <label>Kinga Sonnevend (SE_AOK_Élettan_Admin5_SK, admin)</label>
        <published>true</published>
        <oldId>10031137</oldId>
      </creator>
      <lastDuplumOK>2025-11-18T10:43:19.460+0000</lastDuplumOK>
      <lastDuplumSearch>2025-11-15T16:14:03.829+0000</lastDuplumSearch>
      <core>false</core>
      <publicationPending>false</publicationPending>
      <type>
        <snippet>true</snippet>
        <mtid>24</mtid>
        <code>24</code>
        <link>/api/publicationtype/24</link>
        <otype>PublicationType</otype>
        <label>Journal Article</label>
        <listPosition>1</listPosition>
        <published>true</published>
        <oldId>24</oldId>
        <otypeName>JournalArticle</otypeName>
      </type>
      <subType>
        <snippet>true</snippet>
        <mtid>10000059</mtid>
        <nameEng>Article</nameEng>
        <docType>
          <snippet>true</snippet>
          <mtid>24</mtid>
          <code>24</code>
          <link>/api/publicationtype/24</link>
          <otype>PublicationType</otype>
          <label>Journal Article</label>
          <listPosition>1</listPosition>
          <published>true</published>
          <oldId>24</oldId>
          <otypeName>JournalArticle</otypeName>
        </docType>
        <link>/api/subtype/10000059</link>
        <name>Szakcikk</name>
        <otype>SubType</otype>
        <label>Article (Journal Article)</label>
        <listPosition>101</listPosition>
        <published>true</published>
        <oldId>10000059</oldId>
      </subType>
      <category>
        <snippet>true</snippet>
        <mtid>1</mtid>
        <link>/api/category/1</link>
        <otype>Category</otype>
        <label>Scientific</label>
        <published>true</published>
        <oldId>1</oldId>
      </category>
      <firstAuthor>Aboolian, A.</firstAuthor>
      <title>Diabetic Kidney Disease: From Pathogenesis to Novel Treatment Possibilities</title>
      <journal>
        <snippet>true</snippet>
        <sciIndexed>false</sciIndexed>
        <link>/api/journal/39715</link>
        <reviewType>REVIEWED</reviewType>
        <label>HANDBOOK OF EXPERIMENTAL PHARMACOLOGY 0171-2004 1865-0325</label>
        <published>true</published>
        <hungarian>false</hungarian>
        <oldId>39715</oldId>
        <noIF>true</noIF>
        <mtid>39715</mtid>
        <scopusIndexed>true</scopusIndexed>
        <pIssn>0171-2004</pIssn>
        <eIssn>1865-0325</eIssn>
        <otype>Journal</otype>
        <lang>FOREIGN</lang>
      </journal>
      <volume>274</volume>
      <firstPage>269</firstPage>
      <lastPage>307</lastPage>
      <firstPageOrInternalIdForSort>269</firstPageOrInternalIdForSort>
      <pageLength>39</pageLength>
      <publishedYear>2022</publishedYear>
      <abstractText>One of the microvascular complications of diabetes is diabetic kidney disease (DKD), often leading to end stage renal disease (ESRD) in which patients require costly dialysis or transplantation. The silent onset and irreversible progression of DKD are characterized by a steady decline of the estimated glomerular filtration rate, with or without concomitant albuminuria. The diabetic milieu allows the complex pathophysiology of DKD to enter a vicious cycle by inducing the synthesis of excessive amounts of reactive oxygen species (ROS) causing oxidative stress, inflammation, and fibrosis. As no cure is available, intensive research is required to develop novel treatments possibilities. This chapter provides an overview of the important pathomechanisms identified in diabetic kidney disease, the currently established therapies, as well as recently developed novel therapeutic strategies in DKD. © 2022, The Author(s), under exclusive license to Springer Nature Switzerland AG.</abstractText>
      <digital/>
      <printed/>
      <sourceYear>2022</sourceYear>
      <foreignEdition>true</foreignEdition>
      <foreignLanguage>true</foreignLanguage>
      <fullPublication>true</fullPublication>
      <conferencePublication>false</conferencePublication>
      <nationalOrigin/>
      <missingAuthor>false</missingAuthor>
      <oaType>NONE</oaType>
      <oaCheckDate>2025-11-18</oaCheckDate>
      <oaFree>false</oaFree>
      <citationCount>0</citationCount>
      <citationCountUnpublished>0</citationCountUnpublished>
      <citationCountWoOther>0</citationCountWoOther>
      <independentCitCountWoOther>0</independentCitCountWoOther>
      <doiCitationCount>0</doiCitationCount>
      <wosCitationCount>0</wosCitationCount>
      <scopusCitationCount>0</scopusCitationCount>
      <independentCitationCount>0</independentCitationCount>
      <unhandledCitationCount>0</unhandledCitationCount>
      <citingPubCount>0</citingPubCount>
      <independentCitingPubCount>0</independentCitingPubCount>
      <unhandledCitingPubCount>0</unhandledCitingPubCount>
      <citedPubCount>8</citedPubCount>
      <citedCount>8</citedCount>
      <ratingsForSort>Q4</ratingsForSort>
      <hasCitationDuplums>false</hasCitationDuplums>
      <importDuplum>false</importDuplum>
      <importOverwritten>false</importOverwritten>
      <importSkipped>false</importSkipped>
      <userChangeableUntil>2022-11-07T15:04:21.474+0000</userChangeableUntil>
      <directInstitutesForSort></directInstitutesForSort>
      <ownerAuthorCount>26</ownerAuthorCount>
      <ownerInstituteCount>95</ownerInstituteCount>
      <directInstituteCount>0</directInstituteCount>
      <authorCount>5</authorCount>
      <contributorCount>0</contributorCount>
      <hasQualityFactor>false</hasQualityFactor>
      <languages>
        <language>
          <otype>Language</otype>
          <mtid>10002</mtid>
          <link>/api/language/10002</link>
          <label>English</label>
          <name>Angol</name>
          <nameEng>English</nameEng>
          <published>true</published>
          <oldId>2</oldId>
          <snippet>true</snippet>
        </language>
      </languages>
      <authorships>
        <authorship>
          <otype>PersonAuthorship</otype>
          <mtid>103087991</mtid>
          <link>/api/authorship/103087991</link>
          <label>Aboolian, A.</label>
          <listPosition>1</listPosition>
          <share>0.2</share>
          <first>true</first>
          <last>false</last>
          <corresponding>false</corresponding>
          <familyName>Aboolian</familyName>
          <givenName>A.</givenName>
          <authorTyped>true</authorTyped>
          <editorTyped>false</editorTyped>
          <otherTyped>false</otherTyped>
          <type>
            <otype>AuthorshipType</otype>
            <mtid>1</mtid>
            <link>/api/authorshiptype/1</link>
            <label>Author</label>
            <code>0</code>
            <published>true</published>
            <oldId>0</oldId>
            <snippet>true</snippet>
          </type>
          <published>false</published>
          <snippet>true</snippet>
        </authorship>
        <authorship>
          <otype>PersonAuthorship</otype>
          <mtid>103087992</mtid>
          <link>/api/authorship/103087992</link>
          <label>Urner, S.</label>
          <listPosition>2</listPosition>
          <share>0.2</share>
          <first>false</first>
          <last>false</last>
          <corresponding>false</corresponding>
          <familyName>Urner</familyName>
          <givenName>S.</givenName>
          <authorTyped>true</authorTyped>
          <editorTyped>false</editorTyped>
          <otherTyped>false</otherTyped>
          <type>
            <otype>AuthorshipType</otype>
            <mtid>1</mtid>
            <link>/api/authorshiptype/1</link>
            <label>Author</label>
            <code>0</code>
            <published>true</published>
            <oldId>0</oldId>
            <snippet>true</snippet>
          </type>
          <published>false</published>
          <snippet>true</snippet>
        </authorship>
        <authorship>
          <otype>PersonAuthorship</otype>
          <mtid>103087993</mtid>
          <link>/api/authorship/103087993</link>
          <label>Roden, M.</label>
          <listPosition>3</listPosition>
          <share>0.2</share>
          <first>false</first>
          <last>false</last>
          <corresponding>false</corresponding>
          <familyName>Roden</familyName>
          <givenName>M.</givenName>
          <authorTyped>true</authorTyped>
          <editorTyped>false</editorTyped>
          <otherTyped>false</otherTyped>
          <type>
            <otype>AuthorshipType</otype>
            <mtid>1</mtid>
            <link>/api/authorshiptype/1</link>
            <label>Author</label>
            <code>0</code>
            <published>true</published>
            <oldId>0</oldId>
            <snippet>true</snippet>
          </type>
          <published>false</published>
          <snippet>true</snippet>
        </authorship>
        <authorship>
          <otype>PersonAuthorship</otype>
          <mtid>103087994</mtid>
          <link>/api/authorship/103087994</link>
          <label>Jha, J.C.</label>
          <listPosition>4</listPosition>
          <share>0.2</share>
          <first>false</first>
          <last>false</last>
          <corresponding>false</corresponding>
          <familyName>Jha</familyName>
          <givenName>J.C.</givenName>
          <authorTyped>true</authorTyped>
          <editorTyped>false</editorTyped>
          <otherTyped>false</otherTyped>
          <type>
            <otype>AuthorshipType</otype>
            <mtid>1</mtid>
            <link>/api/authorshiptype/1</link>
            <label>Author</label>
            <code>0</code>
            <published>true</published>
            <oldId>0</oldId>
            <snippet>true</snippet>
          </type>
          <published>false</published>
          <snippet>true</snippet>
        </authorship>
        <authorship>
          <otype>PersonAuthorship</otype>
          <mtid>103087995</mtid>
          <link>/api/authorship/103087995</link>
          <label>Jandeleit-Dahm, K. ✉</label>
          <listPosition>5</listPosition>
          <share>0.2</share>
          <first>false</first>
          <last>true</last>
          <corresponding>true</corresponding>
          <familyName>Jandeleit-Dahm</familyName>
          <givenName>K.</givenName>
          <authorTyped>true</authorTyped>
          <editorTyped>false</editorTyped>
          <otherTyped>false</otherTyped>
          <type>
            <otype>AuthorshipType</otype>
            <mtid>1</mtid>
            <link>/api/authorshiptype/1</link>
            <label>Author</label>
            <code>0</code>
            <published>true</published>
            <oldId>0</oldId>
            <snippet>true</snippet>
          </type>
          <published>false</published>
          <snippet>true</snippet>
        </authorship>
      </authorships>
      <identifiers>
        <identifier>
          <otype>PublicationIdentifier</otype>
          <mtid>21558817</mtid>
          <link>/api/publicationidentifier/21558817</link>
          <label>DOI: 10.1007/164_2021_576</label>
          <source>
            <otype>PlainSource</otype>
            <mtid>6</mtid>
            <link>/api/publicationsource/6</link>
            <label>DOI</label>
            <type>
              <otype>PublicationSourceType</otype>
              <mtid>10001</mtid>
              <link>/api/publicationsourcetype/10001</link>
              <label>DOI</label>
              <mayHaveOa>true</mayHaveOa>
              <published>true</published>
              <snippet>true</snippet>
            </type>
            <name>DOI</name>
            <nameEng>DOI</nameEng>
            <linkPattern>https://doi.org/@@@</linkPattern>
            <publiclyVisible>true</publiclyVisible>
            <published>true</published>
            <oldId>6</oldId>
            <snippet>true</snippet>
          </source>
          <validState>IDENTICAL</validState>
          <idValue>10.1007/164_2021_576</idValue>
          <realUrl>https://doi.org/10.1007/164_2021_576</realUrl>
          <published>false</published>
          <snippet>true</snippet>
        </identifier>
        <identifier>
          <otype>PublicationIdentifier</otype>
          <mtid>28093981</mtid>
          <link>/api/publicationidentifier/28093981</link>
          <label>WoS: 001283235100015</label>
          <source>
            <otype>PlainSource</otype>
            <mtid>1</mtid>
            <link>/api/publicationsource/1</link>
            <label>WoS</label>
            <type>
              <otype>PublicationSourceType</otype>
              <mtid>10003</mtid>
              <link>/api/publicationsourcetype/10003</link>
              <label>Indexelő adatbázis</label>
              <mayHaveOa>false</mayHaveOa>
              <published>true</published>
              <snippet>true</snippet>
            </type>
            <name>WoS</name>
            <nameEng>WoS</nameEng>
            <linkPattern>https://www.webofscience.com/wos/woscc/full-record/@@@</linkPattern>
            <publiclyVisible>true</publiclyVisible>
            <published>true</published>
            <oldId>1</oldId>
            <snippet>true</snippet>
          </source>
          <idValue>001283235100015</idValue>
          <realUrl>https://www.webofscience.com/wos/woscc/full-record/001283235100015</realUrl>
          <published>false</published>
          <snippet>true</snippet>
        </identifier>
        <identifier>
          <otype>PublicationIdentifier</otype>
          <mtid>21558816</mtid>
          <link>/api/publicationidentifier/21558816</link>
          <label>Scopus: 85134855180</label>
          <source>
            <otype>PlainSource</otype>
            <mtid>3</mtid>
            <link>/api/publicationsource/3</link>
            <label>Scopus</label>
            <type>
              <otype>PublicationSourceType</otype>
              <mtid>10003</mtid>
              <link>/api/publicationsourcetype/10003</link>
              <label>Indexelő adatbázis</label>
              <mayHaveOa>false</mayHaveOa>
              <published>true</published>
              <snippet>true</snippet>
            </type>
            <name>Scopus</name>
            <nameEng>Scopus</nameEng>
            <linkPattern>http://www.scopus.com/record/display.url?origin=inward&amp;eid=2-s2.0-@@@</linkPattern>
            <publiclyVisible>true</publiclyVisible>
            <published>true</published>
            <oldId>3</oldId>
            <snippet>true</snippet>
          </source>
          <validState>IDENTICAL</validState>
          <idValue>85134855180</idValue>
          <realUrl>http://www.scopus.com/record/display.url?origin=inward&amp;eid=2-s2.0-85134855180</realUrl>
          <published>false</published>
          <snippet>true</snippet>
        </identifier>
      </identifiers>
      <keywords>
        <keyword>
          <otype>Keyword</otype>
          <mtid>64</mtid>
          <link>/api/keyword/64</link>
          <label>Inflammation</label>
          <published>true</published>
          <oldId>64</oldId>
          <snippet>true</snippet>
        </keyword>
        <keyword>
          <otype>Keyword</otype>
          <mtid>65</mtid>
          <link>/api/keyword/65</link>
          <label>Humans</label>
          <published>true</published>
          <oldId>65</oldId>
          <snippet>true</snippet>
        </keyword>
        <keyword>
          <otype>Keyword</otype>
          <mtid>1267</mtid>
          <link>/api/keyword/1267</link>
          <label>KIDNEY</label>
          <published>true</published>
          <oldId>1267</oldId>
          <snippet>true</snippet>
        </keyword>
        <keyword>
          <otype>Keyword</otype>
          <mtid>3122</mtid>
          <link>/api/keyword/3122</link>
          <label>human</label>
          <published>true</published>
          <oldId>3122</oldId>
          <snippet>true</snippet>
        </keyword>
        <keyword>
          <otype>Keyword</otype>
          <mtid>3126</mtid>
          <link>/api/keyword/3126</link>
          <label>diabetes mellitus</label>
          <published>true</published>
          <oldId>3126</oldId>
          <snippet>true</snippet>
        </keyword>
        <keyword>
          <otype>Keyword</otype>
          <mtid>5639</mtid>
          <link>/api/keyword/5639</link>
          <label>pathology</label>
          <published>true</published>
          <oldId>5639</oldId>
          <snippet>true</snippet>
        </keyword>
        <keyword>
          <otype>Keyword</otype>
          <mtid>10143</mtid>
          <link>/api/keyword/10143</link>
          <label>Albuminuria</label>
          <published>true</published>
          <oldId>10143</oldId>
          <snippet>true</snippet>
        </keyword>
        <keyword>
          <otype>Keyword</otype>
          <mtid>14067</mtid>
          <link>/api/keyword/14067</link>
          <label>Diabetic Nephropathies</label>
          <published>true</published>
          <oldId>14067</oldId>
          <snippet>true</snippet>
        </keyword>
        <keyword>
          <otype>Keyword</otype>
          <mtid>14094</mtid>
          <link>/api/keyword/14094</link>
          <label>diabetic nephropathy</label>
          <published>true</published>
          <oldId>14094</oldId>
          <snippet>true</snippet>
        </keyword>
        <keyword>
          <otype>Keyword</otype>
          <mtid>14362</mtid>
          <link>/api/keyword/14362</link>
          <label>Kidney Failure, Chronic</label>
          <published>true</published>
          <oldId>14362</oldId>
          <snippet>true</snippet>
        </keyword>
        <keyword>
          <otype>Keyword</otype>
          <mtid>14364</mtid>
          <link>/api/keyword/14364</link>
          <label>chronic kidney failure</label>
          <published>true</published>
          <oldId>14364</oldId>
          <snippet>true</snippet>
        </keyword>
        <keyword>
          <otype>Keyword</otype>
          <mtid>21202</mtid>
          <link>/api/keyword/21202</link>
          <label>Fibrosis</label>
          <published>true</published>
          <oldId>21202</oldId>
          <snippet>true</snippet>
        </keyword>
        <keyword>
          <otype>Keyword</otype>
          <mtid>1009906</mtid>
          <link>/api/keyword/1009906</link>
          <label>NADPH OXIDASE</label>
          <published>true</published>
          <oldId>1009906</oldId>
          <snippet>true</snippet>
        </keyword>
        <keyword>
          <otype>Keyword</otype>
          <mtid>1478577</mtid>
          <link>/api/keyword/1478577</link>
          <label>Diabetic kidney disease</label>
          <published>true</published>
          <oldId>1478577</oldId>
          <snippet>true</snippet>
        </keyword>
        <keyword>
          <otype>Keyword</otype>
          <mtid>2014641</mtid>
          <link>/api/keyword/2014641</link>
          <label>Oxidative stress</label>
          <published>true</published>
          <snippet>true</snippet>
        </keyword>
      </keywords>
      <ratings>
        <rating>
          <otype>SjrRating</otype>
          <mtid>11283417</mtid>
          <link>/api/sjrrating/11283417</link>
          <label>sjr:Q4 (2022) Scopus - Biochemistry HANDBOOK OF EXPERIMENTAL PHARMACOLOGY 0171-2004</label>
          <listPos>425</listPos>
          <rankValue>1.0</rankValue>
          <type>journal</type>
          <ratingType>
            <otype>RatingType</otype>
            <mtid>10002</mtid>
            <link>/api/ratingtype/10002</link>
            <label>sjr</label>
            <code>sjr</code>
            <published>true</published>
            <snippet>true</snippet>
          </ratingType>
          <subject>
            <otype>ClassificationExternal</otype>
            <mtid>1303</mtid>
            <link>/api/classificationexternal/1303</link>
            <label>Scopus - Biochemistry</label>
            <published>true</published>
            <oldId>1303</oldId>
            <snippet>true</snippet>
          </subject>
          <ranking>Q4</ranking>
          <calculation>DIRECT</calculation>
          <published>true</published>
          <snippet>true</snippet>
        </rating>
      </ratings>
      <references>
        <reference>
          <otype>Reference</otype>
          <mtid>32764809</mtid>
          <link>/api/reference/32764809</link>
          <label>1. Wiviott, S.D., The design and rationale for the dapagliflozin effect on cardiovascular events (DECLARE)-TIMI 58 trial (2018) Am Heart J, 200, pp. 83-89</label>
          <listPosition>1</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764606</mtid>
          <link>/api/reference/32764606</link>
          <label>2. Adelusi, T.I., Keap1/Nrf2/ARE signaling unfolds therapeutic targets for redox imbalanced-mediated diseases and diabetic nephropathy (2020) Biomed Pharmacother, 123</label>
          <listPosition>2</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764607</mtid>
          <link>/api/reference/32764607</link>
          <label>3. ADVANCE Collaborative Group, Patel A et al (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358(24):2560–2572</label>
          <listPosition>3</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764608</mtid>
          <link>/api/reference/32764608</link>
          <label>4. Altenhofer, S., Evolution of NADPH oxidase inhibitors: Selectivity and mechanisms for target engagement (2015) Antioxid Redox Signal, 23 (5), pp. 406-427</label>
          <listPosition>4</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764609</mtid>
          <link>/api/reference/32764609</link>
          <label>5. Implications of the United Kingdom prospective diabetes study (2000) Diabetes Care, 23, pp. S27-S31. , Suppl 1</label>
          <listPosition>5</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764610</mtid>
          <link>/api/reference/32764610</link>
          <label>6. (2021) Standards of Medical Care in Diabetes-2021, p. 44. , p</label>
          <listPosition>6</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764611</mtid>
          <link>/api/reference/32764611</link>
          <label>7. An, X., The receptor for advanced glycation endproducts mediates podocyte heparanase expression through NF-kappaB signaling pathway (2018) Mol Cell Endocrinol, 470, pp. 14-25</label>
          <listPosition>7</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764612</mtid>
          <link>/api/reference/32764612</link>
          <label>8. Asaba, K., Effects of NADPH oxidase inhibitor in diabetic nephropathy (2005) Kidney Int, 67 (5), pp. 1890-1898</label>
          <listPosition>8</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764613</mtid>
          <link>/api/reference/32764613</link>
          <label>9. Babaei-Jadidi, R., Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine (2003) Diabetes, 52 (8), pp. 2110-2120</label>
          <listPosition>9</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764614</mtid>
          <link>/api/reference/32764614</link>
          <label>10. Badve, S.V., Effects of allopurinol on the progression of chronic kidney disease (2020) N Engl J Med, 382 (26), pp. 2504-2513</label>
          <listPosition>10</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764615</mtid>
          <link>/api/reference/32764615</link>
          <label>11. Bakris, G.L., Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes (2020) N Engl J Med, 383 (23), pp. 2219-2229</label>
          <listPosition>11</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764616</mtid>
          <link>/api/reference/32764616</link>
          <label>12. Bedard, K., Krause, K.H., The NOX family of ROS-generating NADPH oxidases: Physiology and pathophysiology (2007) Physiol Rev, 87 (1), pp. 245-313</label>
          <listPosition>12</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764617</mtid>
          <link>/api/reference/32764617</link>
          <label>13. Beddhu, S., A randomized controlled trial of the effects of febuxostat therapy on adipokines and markers of kidney fibrosis in asymptomatic hyperuricemic patients with diabetic nephropathy (2016) Can J Kidney Health Dis, 3</label>
          <listPosition>13</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764618</mtid>
          <link>/api/reference/32764618</link>
          <label>14. Berthier, C.C., Enhanced expression of Janus kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy (2009) Diabetes, 58 (2), pp. 469-477</label>
          <listPosition>14</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764619</mtid>
          <link>/api/reference/32764619</link>
          <label>15. Bethel, M.A., Renal outcomes in the EXenatide study of cardiovascular event lowering (EXSCEL) (2018) Diabetes, 67, p. 522. , Supplement 1</label>
          <listPosition>15</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764620</mtid>
          <link>/api/reference/32764620</link>
          <label>16. Bhatt, D.L., Sotagliflozin in patients with diabetes and recent worsening heart failure (2021) N Engl J Med, 384 (2), pp. 117-128</label>
          <listPosition>16</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764621</mtid>
          <link>/api/reference/32764621</link>
          <label>17. Block, K., Gorin, Y., Abboud, H.E., Subcellular localization of Nox4 and regulation in diabetes (2009) Proc Natl Acad Sci U S A, 106 (34), pp. 14385-14390</label>
          <listPosition>17</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764622</mtid>
          <link>/api/reference/32764622</link>
          <label>18. Boban, M., Circulating purine compounds, uric acid, and xanthine oxidase/dehydroge-nase relationship in essential hypertension and end stage renal disease (2014) Ren Fail, 36 (4), pp. 613-618</label>
          <listPosition>18</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764623</mtid>
          <link>/api/reference/32764623</link>
          <label>19. Boels, M.G.S., Systemic monocyte chemotactic protein-1 inhibition modifies renal macrophages and restores glomerular endothelial glycocalyx and barrier function in diabetic nephropathy (2017) Am J Pathol, 187 (11), pp. 2430-2440</label>
          <listPosition>19</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764624</mtid>
          <link>/api/reference/32764624</link>
          <label>20. Bolignano, D., Antioxidant agents for delaying diabetic kidney disease progression: A systematic review and meta-analysis (2017) Plos One, 12 (6)</label>
          <listPosition>20</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764625</mtid>
          <link>/api/reference/32764625</link>
          <label>21. Bortolotti, M., Xanthine oxidoreductase: One enzyme for multiple physiological tasks (2021) Redox Biol, 41</label>
          <listPosition>21</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764626</mtid>
          <link>/api/reference/32764626</link>
          <label>22. Brand, M.D., The sites and topology of mitochondrial superoxide production (2010) Exp Gerontol, 45 (7-8), pp. 466-472</label>
          <listPosition>22</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764627</mtid>
          <link>/api/reference/32764627</link>
          <label>23. Brenner, B.M., Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy (2001) N Engl J Med, 345 (12), pp. 861-869</label>
          <listPosition>23</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764628</mtid>
          <link>/api/reference/32764628</link>
          <label>24. Brosius, F.C., Tuttle, K.R., Kretzler, M., JAK inhibition in the treatment of diabetic kidney disease (2016) Diabetologia, 59 (8), pp. 1624-1627</label>
          <listPosition>24</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764629</mtid>
          <link>/api/reference/32764629</link>
          <label>25. Broz, P., Dixit, V.M., Inflammasomes: Mechanism of assembly, regulation and signalling (2016) Nat Rev Immunol, 16 (7), pp. 407-420</label>
          <listPosition>25</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764630</mtid>
          <link>/api/reference/32764630</link>
          <label>26. Cannon, C.P., Cardiovascular outcomes with ertugliflozin in type 2 diabetes (2020) N Engl J Med, 383 (15), pp. 1425-1435</label>
          <listPosition>26</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764631</mtid>
          <link>/api/reference/32764631</link>
          <label>27. Cassis, P., A preclinical overview of emerging therapeutic targets for glomerular diseases (2019) Expert Opin Ther Targets, 23 (7), pp. 593-606</label>
          <listPosition>27</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764632</mtid>
          <link>/api/reference/32764632</link>
          <label>28. Cha, J.J., APX-115, a first-in-class pan-NADPH oxidase (Nox) inhibitor, protects db/db mice from renal injury (2017) Lab Investig, 97 (4), pp. 419-431</label>
          <listPosition>28</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764633</mtid>
          <link>/api/reference/32764633</link>
          <label>29. Chen, K., Regulation of ROS signal transduction by NADPH oxidase 4 localization (2008) J Cell Biol, 181 (7), pp. 1129-1139</label>
          <listPosition>29</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764634</mtid>
          <link>/api/reference/32764634</link>
          <label>30. Chow, F.Y., Intercellular adhesion molecule-1 deficiency is protective against nephropathy in type 2 diabetic db/db mice (2005) J am Soc Nephrol, 16 (6), pp. 1711-1722</label>
          <listPosition>30</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764635</mtid>
          <link>/api/reference/32764635</link>
          <label>31. Chow, F.Y., Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice (2006) Kidney Int, 69 (1), pp. 73-80</label>
          <listPosition>31</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764636</mtid>
          <link>/api/reference/32764636</link>
          <label>32. Chuang, P.Y., Advanced glycation endproducts induce podocyte apoptosis by activation of the FOXO4 transcription factor (2007) Kidney Int, 72 (8), pp. 965-976</label>
          <listPosition>32</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764637</mtid>
          <link>/api/reference/32764637</link>
          <label>33. Colhoun, H.M., Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): Multicentre randomised placebo-controlled trial (2004) Lancet, 364 (9435), pp. 685-696</label>
          <listPosition>33</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764638</mtid>
          <link>/api/reference/32764638</link>
          <label>34. Coll, R.C., MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition (2019) Nat Chem Biol, 15 (6), pp. 556-559</label>
          <listPosition>34</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764639</mtid>
          <link>/api/reference/32764639</link>
          <label>35. Coughlan, M.T., Sharma, K., Challenging the dogma of mitochondrial reactive oxygen species overproduction in diabetic kidney disease (2016) Kidney Int, 90 (2), pp. 272-279</label>
          <listPosition>35</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764640</mtid>
          <link>/api/reference/32764640</link>
          <label>36. Coughlan, M.T., Mapping time-course mitochondrial adaptations in the kidney in experimental diabetes (2016) Clin Sci (Lond), 130 (9), pp. 711-720</label>
          <listPosition>36</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764641</mtid>
          <link>/api/reference/32764641</link>
          <label>37. Dagogo-Jack, S., Screening, monitoring, prevention, and treatment strategies for chronic kidney disease in patients with type 2 diabetes (2021) Chronic Kidney Disease and Type 2 Diabetes, pp. 23-27. , American Diabetes Association, Arlington (VA), pp</label>
          <listPosition>37</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764642</mtid>
          <link>/api/reference/32764642</link>
          <label>38. Darisipudi, M.N., Dual blockade of the homeostatic chemokine CXCL12 and the proinflammatory chemokine CCL2 has additive protective effects on diabetic kidney disease (2011) Am J Pathol, 179 (1), pp. 116-124</label>
          <listPosition>38</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764643</mtid>
          <link>/api/reference/32764643</link>
          <label>39. Davila-Esqueda, M.E., Martinez-Morales, F., Pentoxifylline diminishes the oxidative damage to renal tissue induced by streptozotocin in the rat (2004) Exp Diabesity Res, 5 (4), pp. 245-251</label>
          <listPosition>39</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764644</mtid>
          <link>/api/reference/32764644</link>
          <label>40. Davis, T.M., Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: The fenofibrate intervention and event lowering in diabetes (FIELD) study (2011) Diabetologia, 54 (2), pp. 280-290</label>
          <listPosition>40</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764645</mtid>
          <link>/api/reference/32764645</link>
          <label>41. DCCT/EDIC Research Group, de Boer IH et al (2011) Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med 365(25):2366–2376</label>
          <listPosition>41</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764646</mtid>
          <link>/api/reference/32764646</link>
          <label>42. de Zeeuw, D., Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL (2004) Kidney Int, 65 (6), pp. 2309-2320</label>
          <listPosition>42</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764647</mtid>
          <link>/api/reference/32764647</link>
          <label>43. de Zeeuw, D., Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease (2013) N Engl J Med, 369 (26), pp. 2492-2503</label>
          <listPosition>43</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764648</mtid>
          <link>/api/reference/32764648</link>
          <label>44. Degenhardt, T.P., Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat (2002) Kidney Int, 61 (3), pp. 939-950</label>
          <listPosition>44</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764649</mtid>
          <link>/api/reference/32764649</link>
          <label>45. Nathan, D.M., The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus (1993) N Engl J Med, 329 (14), pp. 977-986</label>
          <listPosition>45</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764650</mtid>
          <link>/api/reference/32764650</link>
          <label>46. Donate-Correa, J., Inflammatory cytokines in diabetic kidney disease: Pathophysiologic and therapeutic implications (2020) Front Med (Lausanne), 7</label>
          <listPosition>46</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764651</mtid>
          <link>/api/reference/32764651</link>
          <label>47. Doria, A., Serum urate lowering with allopurinol and kidney function in type 1 diabetes (2020) N Engl J Med, 382 (26), pp. 2493-2503</label>
          <listPosition>47</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764652</mtid>
          <link>/api/reference/32764652</link>
          <label>48. Dugan, L.L., AMPK dysregulation promotes diabetes-related reduction of superoxide and mitochondrial function (2013) J Clin Invest, 123 (11), pp. 4888-4899</label>
          <listPosition>48</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764653</mtid>
          <link>/api/reference/32764653</link>
          <label>49. Dwyer, J.P., Pyridoxamine dihydrochloride in diabetic nephropathy (PIONEER-CSG-17): Lessons learned from a pilot study (2015) Nephron, 129 (1), pp. 22-28</label>
          <listPosition>49</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764654</mtid>
          <link>/api/reference/32764654</link>
          <label>50. Eli Lilly and Company (2018) Researching cardiovascular events with a weekly incretin in diabetes (REWIND). https://www.clinicaltrials.gov/ct2/show/NCT01394952. Accessed 16 Sep 2021</label>
          <listPosition>50</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764655</mtid>
          <link>/api/reference/32764655</link>
          <label>51. Everett, B.M., Anti-inflammatory therapy with canakinumab for the prevention and management of diabetes (2018) J am Coll Cardiol, 71 (21), pp. 2392-2401</label>
          <listPosition>51</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764656</mtid>
          <link>/api/reference/32764656</link>
          <label>52. Figarola, J.L., LR-90 prevents dyslipidaemia and diabetic nephropathy in the Zucker diabetic fatty rat (2008) Diabetologia, 51 (5), pp. 882-891</label>
          <listPosition>52</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764657</mtid>
          <link>/api/reference/32764657</link>
          <label>53. Filippatos, T.D., SGLT2 inhibitors and cardioprotection: A matter of debate and multiple hypotheses (2019) Postgrad Med, 131 (2), pp. 82-88</label>
          <listPosition>53</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764658</mtid>
          <link>/api/reference/32764658</link>
          <label>54. Fioretto, P., Reversal of lesions of diabetic nephropathy after pancreas transplantation (1998) N Engl J Med, 339 (2), pp. 69-75</label>
          <listPosition>54</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764659</mtid>
          <link>/api/reference/32764659</link>
          <label>55. Frias, J.P., Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (2021) N Engl J Med, 385 (6), pp. 503-515</label>
          <listPosition>55</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764660</mtid>
          <link>/api/reference/32764660</link>
          <label>56. Fulton, D.J., Nox5 and the regulation of cellular function (2009) Antioxid Redox Signal, 11 (10), pp. 2443-2452</label>
          <listPosition>56</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764661</mtid>
          <link>/api/reference/32764661</link>
          <label>57. Galvan, D.L., Green, N.H., Danesh, F.R., The hallmarks of mitochondrial dysfunction in chronic kidney disease (2017) Kidney Int, 92 (5), pp. 1051-1057</label>
          <listPosition>57</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764662</mtid>
          <link>/api/reference/32764662</link>
          <label>58. Galvan, D.L., Real-time in vivo mitochondrial redox assessment confirms enhanced mitochondrial reactive oxygen species in diabetic nephropathy (2017) Kidney Int, 92 (5), pp. 1282-1287</label>
          <listPosition>58</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764663</mtid>
          <link>/api/reference/32764663</link>
          <label>59. Garibotto, G., Toll-like receptor-4 signaling mediates inflammation and tissue injury in diabetic nephropathy (2017) J Nephrol, 30 (6), pp. 719-727</label>
          <listPosition>59</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764664</mtid>
          <link>/api/reference/32764664</link>
          <label>60. Geiszt, M., Identification of renox, an NAD(P)H oxidase in kidney (2000) Proc Natl Acad Sci U S A, 97 (14), pp. 8010-8014</label>
          <listPosition>60</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764665</mtid>
          <link>/api/reference/32764665</link>
          <label>61. Gerstein, H.C., Dulaglutide and renal outcomes in type 2 diabetes: An exploratory analysis of the REWIND randomised, placebo-controlled trial (2019) Lancet, 394, pp. 131-138</label>
          <listPosition>61</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764666</mtid>
          <link>/api/reference/32764666</link>
          <label>62. Gerstein, H.C., Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes (2021) N Engl J Med, 385 (10), pp. 896-907</label>
          <listPosition>62</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764667</mtid>
          <link>/api/reference/32764667</link>
          <label>63. Goicoechea, M., Effect of allopurinol in chronic kidney disease progression and cardiovascular risk (2010) Clin J am Soc Nephrol, 5 (8), pp. 1388-1393</label>
          <listPosition>63</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764668</mtid>
          <link>/api/reference/32764668</link>
          <label>64. Gorin, Y., Nox4 NAD(P)H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney (2005) J Biol Chem, 280 (47), pp. 39616-39626</label>
          <listPosition>64</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764669</mtid>
          <link>/api/reference/32764669</link>
          <label>65. Gorin, Y., Targeting NADPH oxidase with a novel dual Nox1/Nox4 inhibitor attenuates renal pathology in type 1 diabetes (2015) Am J Physiol Renal Physiol, 308 (11), pp. F1276-F1287</label>
          <listPosition>65</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764670</mtid>
          <link>/api/reference/32764670</link>
          <label>66. Gray, S.P., Combined NOX1/4 inhibition with GKT137831 in mice provides dose-dependent Reno-and atheroprotection even in established micro-and macrovascular disease (2017) Diabetologia, 60 (5), pp. 927-937</label>
          <listPosition>66</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764671</mtid>
          <link>/api/reference/32764671</link>
          <label>67. Groop, P.H., The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes (2009) Diabetes, 58 (7), pp. 1651-1658</label>
          <listPosition>67</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764672</mtid>
          <link>/api/reference/32764672</link>
          <label>68. Gueguen, C., Empagliflozin modulates renal sympathetic and heart rate baroreflexes in a rabbit model of diabetes (2020) Diabetologia, 63 (7), pp. 1424-1434</label>
          <listPosition>68</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764673</mtid>
          <link>/api/reference/32764673</link>
          <label>69. Han, Y., Reactive oxygen species promote tubular injury in diabetic nephropathy: The role of the mitochondrial ros-txnip-nlrp3 biological axis (2018) Redox Biol, 16, pp. 32-46</label>
          <listPosition>69</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764674</mtid>
          <link>/api/reference/32764674</link>
          <label>70. He, H., Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity (2018) Nat Commun, 9 (1)</label>
          <listPosition>70</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764675</mtid>
          <link>/api/reference/32764675</link>
          <label>71. Heerspink, H.J.L., Kohan, D.E., de Zeeuw, D., New insights from SONAR indicate adding sodium glucose co-transporter 2 inhibitors to an endothelin receptor antagonist mitigates fluid retention and enhances albuminuria reduction (2021) Kidney Int, 99 (2), pp. 346-349</label>
          <listPosition>71</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764676</mtid>
          <link>/api/reference/32764676</link>
          <label>72. Heumuller, S., Apocynin is not an inhibitor of vascular NADPH oxidases but an antioxidant (2008) Hypertension, 51 (2), pp. 211-217</label>
          <listPosition>72</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764677</mtid>
          <link>/api/reference/32764677</link>
          <label>73. Holman, R.R., 10-year follow-up of intensive glucose control in type 2 diabetes (2008) N Engl J Med, 359 (15), pp. 1577-1589</label>
          <listPosition>73</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764678</mtid>
          <link>/api/reference/32764678</link>
          <label>74. Holman, R.R., Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes (2017) N Engl J Med, 377 (13), pp. 1228-1239</label>
          <listPosition>74</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764679</mtid>
          <link>/api/reference/32764679</link>
          <label>75. Holterman, C.E., Nephropathy and elevated BP in mice with podocyte-specific NADPH oxidase 5 expression (2014) J am Soc Nephrol, 25 (4), pp. 784-797</label>
          <listPosition>75</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764680</mtid>
          <link>/api/reference/32764680</link>
          <label>76. Hong, Q., Increased podocyte Sirtuin-1 function attenuates diabetic kidney injury (2018) Kidney Int, 93 (6), pp. 1330-1343</label>
          <listPosition>76</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764681</mtid>
          <link>/api/reference/32764681</link>
          <label>77. Hou, Y., Mitochondria-targeted peptide SS-31 attenuates renal injury via an antioxidant effect in diabetic nephropathy (2016) Am J Physiol Renal Physiol, 310 (6), pp. F547-F559</label>
          <listPosition>77</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764682</mtid>
          <link>/api/reference/32764682</link>
          <label>78. Hou, B., Salvianolic acid a protects against diabetic nephropathy through ameliorating glomerular endothelial dysfunction via inhibiting AGE-RAGE signaling (2017) Cell Physiol Biochem, 44 (6), pp. 2378-2394</label>
          <listPosition>78</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764683</mtid>
          <link>/api/reference/32764683</link>
          <label>79. Hovind, P., Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: An inception cohort study (2009) Diabetes, 58 (7), pp. 1668-1671</label>
          <listPosition>79</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764684</mtid>
          <link>/api/reference/32764684</link>
          <label>80. Huang, Y., Tranilast directly targets NLRP3 to treat inflammasome-driven diseases (2018) EMBO Mol Med, 10 (4)</label>
          <listPosition>80</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764685</mtid>
          <link>/api/reference/32764685</link>
          <label>81. Hutton, H.L., The NLRP3 inflammasome in kidney disease and autoimmunity (2016) Nephrology (Carlton), 21 (9), pp. 736-744</label>
          <listPosition>81</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764686</mtid>
          <link>/api/reference/32764686</link>
          <label>82. Jensen, L.J., Renal effects of a neutralising RAGE-antibody in long-term streptozotocin-diabetic mice (2006) J Endocrinol, 188 (3), pp. 493-501</label>
          <listPosition>82</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764687</mtid>
          <link>/api/reference/32764687</link>
          <label>83. Jha, J.C., Genetic targeting or pharmacologic inhibition of NADPH oxidase nox4 provides renoprotection in long-term diabetic nephropathy (2014) J am Soc Nephrol, 25 (6), pp. 1237-1254</label>
          <listPosition>83</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764688</mtid>
          <link>/api/reference/32764688</link>
          <label>84. Jha, J.C., Diabetes and kidney disease: Role of oxidative stress (2016) Antioxid Redox Signal, 25 (12), pp. 657-684</label>
          <listPosition>84</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764689</mtid>
          <link>/api/reference/32764689</link>
          <label>85. Jha, J.C., Podocyte-specific Nox4 deletion affords renoprotection in a mouse model of diabetic nephropathy (2016) Diabetologia, 59 (2), pp. 379-389</label>
          <listPosition>85</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764690</mtid>
          <link>/api/reference/32764690</link>
          <label>86. Jha, J.C., NADPH oxidase Nox5 accelerates renal injury in diabetic nephropathy (2017) Diabetes, 66 (10), pp. 2691-2703</label>
          <listPosition>86</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764691</mtid>
          <link>/api/reference/32764691</link>
          <label>87. Jha, J.C., A causal link between oxidative stress and inflammation in cardiovascular and renal complications of diabetes (2018) Clin Sci (Lond), 132 (16), pp. 1811-1836</label>
          <listPosition>87</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764692</mtid>
          <link>/api/reference/32764692</link>
          <label>88. Jiang, T., The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy (2010) Diabetes, 59 (4), pp. 850-860</label>
          <listPosition>88</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764693</mtid>
          <link>/api/reference/32764693</link>
          <label>89. Jourde-Chiche, N., Endothelium structure and function in kidney health and disease (2019) Nat Rev Nephrol, 15 (2), pp. 87-108</label>
          <listPosition>89</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764694</mtid>
          <link>/api/reference/32764694</link>
          <label>90. Kanwar, Y.S., Diabetic nephropathy: Mechanisms of renal disease progression (2008) Exp Biol Med (Maywood), 233 (1), pp. 4-11</label>
          <listPosition>90</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764695</mtid>
          <link>/api/reference/32764695</link>
          <label>91. Kidney Disease: Improving Global Outcomes Diabetes Work Group (2020) KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease Kidney Int, 98 (4S), pp. S1-S115</label>
          <listPosition>91</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764696</mtid>
          <link>/api/reference/32764696</link>
          <label>92. Kimura, K., Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: A randomized trial (2018) Am J Kidney Dis, 72 (6), pp. 798-810</label>
          <listPosition>92</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764697</mtid>
          <link>/api/reference/32764697</link>
          <label>93. Komers, R., Effects of xanthine oxidase inhibition with febuxostat on the development of nephropathy in experimental type 2 diabetes (2016) Br J Pharmacol, 173 (17), pp. 2573-2588</label>
          <listPosition>93</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764698</mtid>
          <link>/api/reference/32764698</link>
          <label>94. Kosugi, T., Effect of lowering uric acid on renal disease in the type 2 diabetic db/db mice (2009) Am J Physiol Renal Physiol, 297 (2), pp. F481-F488</label>
          <listPosition>94</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764699</mtid>
          <link>/api/reference/32764699</link>
          <label>95. Kovac, S., Nrf2 regulates ROS production by mitochondria and NADPH oxidase (2015) Biochim Biophys Acta, 1850 (4), pp. 794-801</label>
          <listPosition>95</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764700</mtid>
          <link>/api/reference/32764700</link>
          <label>96. Krishnan, S.M., Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure, renal damage, and dysfunction in salt-sensitive hypertension (2019) Cardiovasc Res, 115 (4), pp. 776-787</label>
          <listPosition>96</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764701</mtid>
          <link>/api/reference/32764701</link>
          <label>97. Kwon, G., A novel pan-Nox inhibitor, APX-115, protects kidney injury in streptozotocin-induced diabetic mice: possible role of peroxisomal and mitochondrial biogenesis (2017) Oncotarget, 8 (43), pp. 74217-74232</label>
          <listPosition>97</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764702</mtid>
          <link>/api/reference/32764702</link>
          <label>98. Lamkanfi, M., Dixit, V.M., Mechanisms and functions of inflammasomes (2014) Cell, 157 (5), pp. 1013-1022</label>
          <listPosition>98</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764703</mtid>
          <link>/api/reference/32764703</link>
          <label>99. Lassen, E., Daehn, I.S., Molecular mechanisms in early diabetic kidney disease: Glomerular endothelial cell dysfunction (2020) Int J Mol Sci, 21 (24), p. 9456</label>
          <listPosition>99</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764704</mtid>
          <link>/api/reference/32764704</link>
          <label>100. Lee, H.J., Febuxostat ameliorates diabetic renal injury in a streptozotocin-induced diabetic rat model (2014) Am J Nephrol, 40 (1), pp. 56-63</label>
          <listPosition>100</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764705</mtid>
          <link>/api/reference/32764705</link>
          <label>101. Lee, E.S., APX-115, a pan-NADPH oxidase inhibitor, protects development of diabetic nephropathy in podocyte specific NOX5 transgenic mice (2020) Free Radic Biol Med, 161, pp. 92-101</label>
          <listPosition>101</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764706</mtid>
          <link>/api/reference/32764706</link>
          <label>102. Lewis, E.J., The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The collaborative study group (1993) N Engl J Med, 329 (20), pp. 1456-1462</label>
          <listPosition>102</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764707</mtid>
          <link>/api/reference/32764707</link>
          <label>103. Lewis, E.J., Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes (2001) N Engl J Med, 345 (12), pp. 851-860</label>
          <listPosition>103</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764708</mtid>
          <link>/api/reference/32764708</link>
          <label>104. Li, J., Oridonin protects against the inflammatory response in diabetic nephropathy by inhibiting the TLR4/p38-MAPK and TLR4/NF-kappaB signaling pathways (2018) Int Immunopharmacol, 55, pp. 9-19</label>
          <listPosition>104</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764709</mtid>
          <link>/api/reference/32764709</link>
          <label>105. Lim, A.K., Tesch, G.H., Inflammation in diabetic nephropathy (2012) Mediat Inflamm, 2012</label>
          <listPosition>105</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764710</mtid>
          <link>/api/reference/32764710</link>
          <label>106. Lin, J.S., Susztak, K., Podocytes: The weakest link in diabetic kidney disease? (2016) Curr Diab Rep, 16 (5)</label>
          <listPosition>106</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764711</mtid>
          <link>/api/reference/32764711</link>
          <label>107. Lin, S.L., Pentoxifylline attenuated the renal disease progression in rats with remnant kidney (2002) J am Soc Nephrol, 13 (12), pp. 2916-2929</label>
          <listPosition>107</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764712</mtid>
          <link>/api/reference/32764712</link>
          <label>108. Lin, S.L., Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: A 12-month randomized trial (2008) Am J Kidney Dis, 52 (3), pp. 464-474</label>
          <listPosition>108</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764713</mtid>
          <link>/api/reference/32764713</link>
          <label>109. Lin, M., Toll-like receptor 4 promotes tubular inflammation in diabetic nephropathy (2012) J am Soc Nephrol, 23 (1), pp. 86-102</label>
          <listPosition>109</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764714</mtid>
          <link>/api/reference/32764714</link>
          <label>110. Loeffler, I., Wolf, G., Epithelial-to-mesenchymal transition in diabetic nephropathy: Fact or fiction? (2015) Cell, 4 (4), pp. 631-652</label>
          <listPosition>110</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764715</mtid>
          <link>/api/reference/32764715</link>
          <label>111. Lonn, E., Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: Results of the HOPE study and MICRO-HOPE substudy (2002) Diabetes Care, 25 (11), pp. 1919-1927</label>
          <listPosition>111</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764716</mtid>
          <link>/api/reference/32764716</link>
          <label>112. Macisaac, R.J., Jerums, G., Diabetic kidney disease with and without albuminuria (2011) Curr Opin Nephrol Hypertens, 20 (3), pp. 246-257</label>
          <listPosition>112</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764717</mtid>
          <link>/api/reference/32764717</link>
          <label>113. Mann, J.F., Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial (2008) Lancet, 372 (9638), pp. 547-553</label>
          <listPosition>113</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764718</mtid>
          <link>/api/reference/32764718</link>
          <label>114. Mann, J.F., Avosentan for overt diabetic nephropathy (2010) J am Soc Nephrol, 21 (3), pp. 527-535</label>
          <listPosition>114</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764719</mtid>
          <link>/api/reference/32764719</link>
          <label>115. Marshall, C.B., Rethinking glomerular basement membrane thickening in diabetic nephropathy: Adaptive or pathogenic? (2016) Am J Physiol Renal Physiol, 311 (5), pp. F831-F843</label>
          <listPosition>115</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764720</mtid>
          <link>/api/reference/32764720</link>
          <label>116. Marso, S.P., Liraglutide and cardiovascular outcomes in type 2 diabetes (2016) N Engl J Med, 375 (4), pp. 311-322</label>
          <listPosition>116</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764721</mtid>
          <link>/api/reference/32764721</link>
          <label>117. Marso, S.P., Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (2016) N Engl J Med, 375 (19), pp. 1834-1844</label>
          <listPosition>117</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764722</mtid>
          <link>/api/reference/32764722</link>
          <label>118. Martyn, K.D., Functional analysis of Nox4 reveals unique characteristics compared to other NADPH oxidases (2006) Cell Signal, 18 (1), pp. 69-82</label>
          <listPosition>118</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764723</mtid>
          <link>/api/reference/32764723</link>
          <label>119. Mason, R.M., Wahab, N.A., Extracellular matrix metabolism in diabetic nephropathy (2003) J am Soc Nephrol, 14 (5), pp. 1358-1373</label>
          <listPosition>119</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764724</mtid>
          <link>/api/reference/32764724</link>
          <label>120. Matsui, T., RAGE-aptamer blocks the development and progression of experimental diabetic nephropathy (2017) Diabetes, 66 (6), pp. 1683-1695</label>
          <listPosition>120</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764725</mtid>
          <link>/api/reference/32764725</link>
          <label>121. McCullough, P.A., Independent components of chronic kidney disease as a cardiovascular risk state: Results from the kidney early evaluation program (KEEP) (2007) Arch Intern Med, 167 (11), pp. 1122-1129</label>
          <listPosition>121</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764726</mtid>
          <link>/api/reference/32764726</link>
          <label>122. McGuire, D.K., Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: A meta-analysis (2021) JAMA Cardiol, 6 (2), pp. 148-158</label>
          <listPosition>122</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764727</mtid>
          <link>/api/reference/32764727</link>
          <label>123. McMurray, J.J.V., Effect of dapagliflozin on clinical outcomes in patients with chronic kidney disease, with and without cardiovascular disease (2021) Circulation, 143 (5), pp. 438-448</label>
          <listPosition>123</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764728</mtid>
          <link>/api/reference/32764728</link>
          <label>124. Menini, S., The inflammasome in chronic complications of diabetes and related metabolic disorders (2020) Cell, 9 (8)</label>
          <listPosition>124</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764729</mtid>
          <link>/api/reference/32764729</link>
          <label>125. Menne, J., C-C motif-ligand 2 inhibition with emapticap pegol (NOX-E36) in type 2 diabetic patients with albuminuria (2017) Nephrol Dial Transplant, 32 (2), pp. 307-315</label>
          <listPosition>125</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764730</mtid>
          <link>/api/reference/32764730</link>
          <label>126. Mills, K.T., Sodium excretion and the risk of cardiovascular disease in patients with chronic kidney disease (2016) JAMA, 315 (20), pp. 2200-2210</label>
          <listPosition>126</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764731</mtid>
          <link>/api/reference/32764731</link>
          <label>127. Mise, K., Galvan, D.L., Danesh, F.R., Shaping up mitochondria in diabetic nephropathy (2020) Kidney360, 1 (9), pp. 982-992</label>
          <listPosition>127</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764732</mtid>
          <link>/api/reference/32764732</link>
          <label>128. Mundel, P., Shankland, S.J., Podocyte biology and response to injury (2002) J am Soc Nephrol, 13 (12), pp. 3005-3015</label>
          <listPosition>128</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764733</mtid>
          <link>/api/reference/32764733</link>
          <label>129. Murphy, M.P., How mitochondria produce reactive oxygen species (2009) Biochem J, 417 (1), pp. 1-13</label>
          <listPosition>129</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764734</mtid>
          <link>/api/reference/32764734</link>
          <label>130. Murray, D.P., Is dietary protein intake predictive of 1-year mortality in dialysis patients? (2018) Am J Med Sci, 356 (3), pp. 234-243</label>
          <listPosition>130</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764735</mtid>
          <link>/api/reference/32764735</link>
          <label>131. Nakamura, S., Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation (1997) Diabetes, 46 (5), pp. 895-899</label>
          <listPosition>131</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764736</mtid>
          <link>/api/reference/32764736</link>
          <label>132. Nangaku, M., Randomized clinical trial on the effect of bardoxolone methyl on GFR in diabetic kidney disease patients (TSUBAKI study) (2020) Kidney Int Rep, 5 (6), pp. 879-890</label>
          <listPosition>132</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764737</mtid>
          <link>/api/reference/32764737</link>
          <label>133. Navarro, J.F., Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: Effects of pentoxifylline administration (1999) Am J Kidney Dis, 33 (3), pp. 458-463</label>
          <listPosition>133</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764738</mtid>
          <link>/api/reference/32764738</link>
          <label>134. Navarro, J.F., Effects of pentoxifylline administration on urinary N-acetyl-beta-glucosaminidase excretion in type 2 diabetic patients: A short-term, prospective, randomized study (2003) Am J Kidney Dis, 42 (2), pp. 264-270</label>
          <listPosition>134</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764739</mtid>
          <link>/api/reference/32764739</link>
          <label>135. Navarro, J.F., Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: A short-term, randomized, controlled trial (2005) J am Soc Nephrol, 16 (7), pp. 2119-2126</label>
          <listPosition>135</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764740</mtid>
          <link>/api/reference/32764740</link>
          <label>136. Navarro-Gonzalez, J.F., Mora-Fernandez, C., The role of inflammatory cytokines in diabetic nephropathy (2008) J am Soc Nephrol, 19 (3), pp. 433-442</label>
          <listPosition>136</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764741</mtid>
          <link>/api/reference/32764741</link>
          <label>137. Navarro-Gonzalez, J.F., Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: The PREDIAN trial (2015) J am Soc Nephrol, 26 (1), pp. 220-229</label>
          <listPosition>137</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764742</mtid>
          <link>/api/reference/32764742</link>
          <label>138. Neal, B., Perkovic, V., Matthews, D.R., Canagliflozin and cardiovascular and renal events in type 2 diabetes (2017) N Engl J Med, 377 (21), p. 2099</label>
          <listPosition>138</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764743</mtid>
          <link>/api/reference/32764743</link>
          <label>139. Ninichuk, V., Late onset of Ccl2 blockade with the Spiegelmer mNOX-E36-3'PEG prevents glomerulosclerosis and improves glomerular filtration rate in db/db mice (2008) Am J Pathol, 172 (3), pp. 628-637</label>
          <listPosition>139</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764744</mtid>
          <link>/api/reference/32764744</link>
          <label>140. Nolfi-Donegan, D., Braganza, A., Shiva, S., Mitochondrial electron transport chain: Oxidative phosphorylation, oxidant production, and methods of measurement (2020) Redox Biol, 37</label>
          <listPosition>140</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764745</mtid>
          <link>/api/reference/32764745</link>
          <label>141. Novo Nordisk A/S (2021) A research study to see how semaglutide works compared to placebo in people with type 2 diabetes and chronic kidney disease (FLOW). https://clinicaltrials.gov/ct2/show/NCT03819153. Accessed 1 Sept 2021</label>
          <listPosition>141</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764746</mtid>
          <link>/api/reference/32764746</link>
          <label>142. Ostergaard, J.A., Adverse renal effects of NLRP3 inflammasome inhibition by MCC950 in an interventional model of diabetic kidney disease (2022) Clin Sci, , in press</label>
          <listPosition>142</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764747</mtid>
          <link>/api/reference/32764747</link>
          <label>143. Ostergaard, J.A., Cooper, M.E., Jandeleit-Dahm, K.A.M., Targeting oxidative stress and antioxidant defence in diabetic kidney disease (2020) J Nephrol, 33 (5), pp. 917-929</label>
          <listPosition>143</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764748</mtid>
          <link>/api/reference/32764748</link>
          <label>144. Pacher, P., Nivorozhkin, A., Szabo, C., Therapeutic effects of xanthine oxidase inhibitors: Renaissance half a century after the discovery of allopurinol (2006) Pharmacol Rev, 58 (1), pp. 87-114</label>
          <listPosition>144</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764749</mtid>
          <link>/api/reference/32764749</link>
          <label>145. Parving, H.H., The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes (2001) N Engl J Med, 345 (12), pp. 870-878</label>
          <listPosition>145</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764750</mtid>
          <link>/api/reference/32764750</link>
          <label>146. Parving, H.H., Cardiorenal end points in a trial of aliskiren for type 2 diabetes (2012) N Engl J Med, 367 (23), pp. 2204-2213</label>
          <listPosition>146</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764751</mtid>
          <link>/api/reference/32764751</link>
          <label>147. Penno, G., Insulin resistance, diabetic kidney disease, and all-cause mortality in individuals with type 2 diabetes: A prospective cohort study (2021) BMC Med, 19 (1)</label>
          <listPosition>147</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764752</mtid>
          <link>/api/reference/32764752</link>
          <label>148. Pergola, P.E., Effect of bardoxolone methyl on kidney function in patients with T2D and stage 3b-4 CKD (2011) Am J Nephrol, 33 (5), pp. 469-476</label>
          <listPosition>148</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764753</mtid>
          <link>/api/reference/32764753</link>
          <label>149. Pergola, P.E., Bardoxolone methyl and kidney function in CKD with type 2 diabetes (2011) N Engl J Med, 365 (4), pp. 327-336</label>
          <listPosition>149</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764754</mtid>
          <link>/api/reference/32764754</link>
          <label>150. Perkovic, V., Canagliflozin and renal outcomes in type 2 diabetes and nephropathy (2019) N Engl J Med, 380 (24), pp. 2295-2306</label>
          <listPosition>150</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764755</mtid>
          <link>/api/reference/32764755</link>
          <label>151. Petrilli, V., Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration (2007) Cell Death Differ, 14 (9), pp. 1583-1589</label>
          <listPosition>151</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764756</mtid>
          <link>/api/reference/32764756</link>
          <label>152. Pickering, R.J., Transactivation of RAGE mediates angiotensin-induced inflammation and atherogenesis (2019) J Clin Invest, 129 (1), pp. 406-421</label>
          <listPosition>152</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764757</mtid>
          <link>/api/reference/32764757</link>
          <label>153. Pisano, A., Xanthine oxidase inhibitors for improving renal function in chronic kidney disease patients: An updated systematic review and meta-analysis (2017) Int J Mol Sci, 18 (11), p. 2283</label>
          <listPosition>153</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764758</mtid>
          <link>/api/reference/32764758</link>
          <label>154. Plantinga, L.C., Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes (2010) Clin J am Soc Nephrol, 5 (4), pp. 673-682</label>
          <listPosition>154</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764759</mtid>
          <link>/api/reference/32764759</link>
          <label>155. Qian, Y., From fibrosis to sclerosis: Mechanisms of glomerulosclerosis in diabetic nephropathy (2008) Diabetes, 57 (6), pp. 1439-1445</label>
          <listPosition>155</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764760</mtid>
          <link>/api/reference/32764760</link>
          <label>156. Qin, J., AKF-PD alleviates diabetic nephropathy via blocking the RAGE/AGEs/NOX and PKC/NOX pathways (2019) Sci Rep, 9 (1)</label>
          <listPosition>156</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764761</mtid>
          <link>/api/reference/32764761</link>
          <label>157. Rajaram, R.D., Tubular NOX4 expression decreases in chronic kidney disease but does not modify fibrosis evolution (2019) Redox Biol, 26</label>
          <listPosition>157</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764762</mtid>
          <link>/api/reference/32764762</link>
          <label>158. Ram, C., Targeting NLRP3 inflammasome as a promising approach for treatment of diabetic nephropathy: Preclinical evidences with therapeutic approaches (2020) Eur J Pharmacol, 885</label>
          <listPosition>158</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764763</mtid>
          <link>/api/reference/32764763</link>
          <label>159. Reddy, M.A., Zhang, E., Natarajan, R., Epigenetic mechanisms in diabetic complications and metabolic memory (2015) Diabetologia, 58 (3), pp. 443-455</label>
          <listPosition>159</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764764</mtid>
          <link>/api/reference/32764764</link>
          <label>160. Reidy, K., Molecular mechanisms of diabetic kidney disease (2014) J Clin Invest, 124 (6), pp. 2333-2340</label>
          <listPosition>160</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764765</mtid>
          <link>/api/reference/32764765</link>
          <label>161. Reutens, A.T., A physician-initiated double-blind, randomised, placebo-controlled, phase 2 study evaluating the efficacy and safety of inhibition of NADPH oxidase with the first-in-class Nox-1/4 inhibitor, GKT137831, in adults with type 1 diabetes and persistently elevated urinary albumin excretion: Protocol and statistical considerations (2020) Contemp Clin Trials, 90</label>
          <listPosition>161</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764766</mtid>
          <link>/api/reference/32764766</link>
          <label>162. Ridker, P.M., Antiinflammatory therapy with canakinumab for atherosclerotic disease (2017) N Engl J Med, 377 (12), pp. 1119-1131</label>
          <listPosition>162</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764767</mtid>
          <link>/api/reference/32764767</link>
          <label>163. Ridker, P.M., Inhibition of interleukin-1beta by canakinumab and cardiovascular outcomes in patients with chronic kidney disease (2018) J am Coll Cardiol, 71 (21), pp. 2405-2414</label>
          <listPosition>163</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764768</mtid>
          <link>/api/reference/32764768</link>
          <label>164. Rosenstock, J., Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): A double-blind, randomised, phase 3 trial (2021) Lancet, 398, pp. 143-155</label>
          <listPosition>164</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764769</mtid>
          <link>/api/reference/32764769</link>
          <label>165. Samra, Y.A., Cepharanthine and piperine ameliorate diabetic nephropathy in rats: Role of NF-kappaB and NLRP3 inflammasome (2016) Life Sci, 157, pp. 187-199</label>
          <listPosition>165</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764770</mtid>
          <link>/api/reference/32764770</link>
          <label>166. Sanajou, D., AGE-RAGE axis blockade in diabetic nephropathy: Current status and future directions (2018) Eur J Pharmacol, 833, pp. 158-164</label>
          <listPosition>166</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764771</mtid>
          <link>/api/reference/32764771</link>
          <label>167. Schiffer, T.A., Friedrich-Persson, M., Mitochondrial reactive oxygen species and kidney hypoxia in the development of diabetic nephropathy (2017) Front Physiol, 8, p. 211</label>
          <listPosition>167</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764772</mtid>
          <link>/api/reference/32764772</link>
          <label>168. Schmit, D., Fliser, D., Speer, T., Proprotein convertase subtilisin/kexin type 9 in kidney disease (2019) Nephrol Dial Transplant, 34 (8), pp. 1266-1271</label>
          <listPosition>168</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764773</mtid>
          <link>/api/reference/32764773</link>
          <label>169. Schnell, O., Report from the 5th cardiovascular outcome trial (CVOT) summit (2020) Cardiovasc Diabetol, 19 (1)</label>
          <listPosition>169</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764774</mtid>
          <link>/api/reference/32764774</link>
          <label>170. Sedeek, M., Critical role of Nox4-based NADPH oxidase in glucose-induced oxidative stress in the kidney: Implications in type 2 diabetic nephropathy (2010) Am J Physiol Renal Physiol, 299 (6), pp. F1348-F1358</label>
          <listPosition>170</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764775</mtid>
          <link>/api/reference/32764775</link>
          <label>171. Sedeek, M., Renoprotective effects of a novel Nox1/4 inhibitor in a mouse model of type 2 diabetes (2013) Clin Sci (Lond), 124 (3), pp. 191-202</label>
          <listPosition>171</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764776</mtid>
          <link>/api/reference/32764776</link>
          <label>172. Serrander, L., NOX5 is expressed at the plasma membrane and generates superoxide in response to protein kinase C activation (2007) Biochimie, 89 (9), pp. 1159-1167</label>
          <listPosition>172</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764777</mtid>
          <link>/api/reference/32764777</link>
          <label>173. Sharma, A., Specific NLRP3 inhibition protects against diabetes-associated atherosclerosis (2021) Diabetes, 70 (3), pp. 772-787</label>
          <listPosition>173</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764778</mtid>
          <link>/api/reference/32764778</link>
          <label>174. Shen, X., Efficacy of statins in patients with diabetic nephropathy: A meta-analysis of randomized controlled trials (2016) Lipids Health Dis, 15 (1)</label>
          <listPosition>174</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764779</mtid>
          <link>/api/reference/32764779</link>
          <label>175. Sircar, D., Efficacy of febuxostat for slowing the GFR decline in patients with CKD and asymptomatic hyperuricemia: A 6-month, double-blind, randomized, placebo-controlled trial (2015) Am J Kidney Dis, 66 (6), pp. 945-950</label>
          <listPosition>175</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764780</mtid>
          <link>/api/reference/32764780</link>
          <label>176. Siu, Y.P., Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level (2006) Am J Kidney Dis, 47 (1), pp. 51-59</label>
          <listPosition>176</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764781</mtid>
          <link>/api/reference/32764781</link>
          <label>177. Sleight, P., The HOPE study (heart outcomes prevention evaluation) (2000) J Renin-Angiotensin-Aldosterone Syst, 1 (1), pp. 18-20</label>
          <listPosition>177</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764782</mtid>
          <link>/api/reference/32764782</link>
          <label>178. Solini, A., The purinergic 2X7 receptor participates in renal inflammation and injury induced by high-fat diet: Possible role of NLRP3 inflammasome activation (2013) J Pathol, 231 (3), pp. 342-353</label>
          <listPosition>178</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764783</mtid>
          <link>/api/reference/32764783</link>
          <label>179. Soma, J., Effect of tranilast in early-stage diabetic nephropathy (2006) Nephrol Dial Transplant, 21 (10), pp. 2795-2799</label>
          <listPosition>179</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764784</mtid>
          <link>/api/reference/32764784</link>
          <label>180. Sourris, K.C., Ubiquinone (coenzyme Q10) prevents renal mitochondrial dysfunction in an experimental model of type 2 diabetes (2012) Free Radic Biol Med, 52 (3), pp. 716-723</label>
          <listPosition>180</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764785</mtid>
          <link>/api/reference/32764785</link>
          <label>181. Steffes, M.W., Cell and matrix components of the glomerular mesangium in type I diabetes (1992) Diabetes, 41 (6), pp. 679-684</label>
          <listPosition>181</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764786</mtid>
          <link>/api/reference/32764786</link>
          <label>182. Steno Diabetes Center Copenhagen (2019) Renal effects of treatment with empagliflozin alone or in combination with semaglutide in patients with type 2 diabetes and albuminuria (EmpaSema). https://clinicaltrials.gov/ct2/show/NCT04061200. Accessed 01 Sep 2021</label>
          <listPosition>182</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764787</mtid>
          <link>/api/reference/32764787</link>
          <label>183. Stratton, I.M., Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study (2000) BMJ, 321 (7258), pp. 405-412</label>
          <listPosition>183</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764788</mtid>
          <link>/api/reference/32764788</link>
          <label>184. Strutz, F., Effects of pentoxifylline, pentifylline and gamma-interferon on proliferation, differentiation, and matrix synthesis of human renal fibroblasts (2000) Nephrol Dial Transplant, 15 (10), pp. 1535-1546</label>
          <listPosition>184</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764789</mtid>
          <link>/api/reference/32764789</link>
          <label>185. Takac, I., The E-loop is involved in hydrogen peroxide formation by the NADPH oxidase Nox4 (2011) J Biol Chem, 286 (15), pp. 13304-13313</label>
          <listPosition>185</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764790</mtid>
          <link>/api/reference/32764790</link>
          <label>186. Tashiro, K., Urinary levels of monocyte chemoattractant protein-1 (MCP-1) and interleukin-8 (IL-8), and renal injuries in patients with type 2 diabetic nephropathy (2002) J Clin Lab Anal, 16 (1), pp. 1-4</label>
          <listPosition>186</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764791</mtid>
          <link>/api/reference/32764791</link>
          <label>187. Thallas-Bonke, V., Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway (2008) Diabetes, 57 (2), pp. 460-469</label>
          <listPosition>187</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764792</mtid>
          <link>/api/reference/32764792</link>
          <label>188. Thallas-Bonke, V., Targeted deletion of nicotinamide adenine dinucleotide phosphate oxidase 4 from proximal tubules is dispensable for diabetic kidney disease development (2021) Nephrol Dial Transplant, 36 (6), pp. 988-997</label>
          <listPosition>188</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764793</mtid>
          <link>/api/reference/32764793</link>
          <label>189. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data (2001) Ann Intern Med, 134 (5), pp. 370-379</label>
          <listPosition>189</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764794</mtid>
          <link>/api/reference/32764794</link>
          <label>190. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial (1995) Kidney Int, 47 (6), pp. 1703-1720</label>
          <listPosition>190</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764795</mtid>
          <link>/api/reference/32764795</link>
          <label>191. The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group, Steffes M et al (2003) Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 290(16):2159–2167</label>
          <listPosition>191</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764796</mtid>
          <link>/api/reference/32764796</link>
          <label>192. Tsalamandris, C., Progressive decline in renal function in diabetic patients with and without albuminuria (1994) Diabetes, 43 (5), pp. 649-655</label>
          <listPosition>192</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764797</mtid>
          <link>/api/reference/32764797</link>
          <label>193. Tung, C.W., Glomerular mesangial cell and podocyte injuries in diabetic nephropathy (2018) Nephrology (Carlton), 23, pp. 32-37</label>
          <listPosition>193</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764798</mtid>
          <link>/api/reference/32764798</link>
          <label>194. Tuttle, K.R., Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): A multicentre, open-label, randomised trial (2018) Lancet Diabetes Endocrinol, 6 (8), pp. 605-617</label>
          <listPosition>194</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764799</mtid>
          <link>/api/reference/32764799</link>
          <label>195. Tuttle, K.R., JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: Results from a phase 2 randomized controlled clinical trial (2018) Nephrol Dial Transplant, 33 (11), pp. 1950-1959</label>
          <listPosition>195</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764800</mtid>
          <link>/api/reference/32764800</link>
          <label>196. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) (1998) Lancet, 352 (9131), pp. 837-853</label>
          <listPosition>196</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764801</mtid>
          <link>/api/reference/32764801</link>
          <label>197. Urner, S., NADPH oxidase inhibition: Preclinical and clinical studies in diabetic complications (2020) Antioxid Redox Signal, 33 (6), pp. 415-434</label>
          <listPosition>197</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764802</mtid>
          <link>/api/reference/32764802</link>
          <label>198. van den Hoven, M.J., Regulation of glomerular heparanase expression by aldosterone, angiotensin II and reactive oxygen species (2009) Nephrol Dial Transplant, 24 (9), pp. 2637-2645</label>
          <listPosition>198</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764803</mtid>
          <link>/api/reference/32764803</link>
          <label>199. Viberti, G., Wheeldon, N.M., MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators (2002) Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: A blood pressure-independent effect Circulation, 106 (6), pp. 672-678</label>
          <listPosition>199</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764804</mtid>
          <link>/api/reference/32764804</link>
          <label>200. Vilaysane, A., The NLRP3 inflammasome promotes renal inflammation and contributes to CKD (2010) J am Soc Nephrol, 21 (10), pp. 1732-1744</label>
          <listPosition>200</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764805</mtid>
          <link>/api/reference/32764805</link>
          <label>201. Wanner, C., Empagliflozin and progression of kidney disease in type 2 diabetes (2016) N Engl J Med, 375 (4), pp. 323-334</label>
          <listPosition>201</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764806</mtid>
          <link>/api/reference/32764806</link>
          <label>202. Ward, M.S., Targeted mitochondrial therapy using MitoQ shows equivalent renoprotection to angiotensin converting enzyme inhibition but no combined synergy in diabetes (2017) Sci Rep, 7 (1)</label>
          <listPosition>202</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764807</mtid>
          <link>/api/reference/32764807</link>
          <label>203. Watson, A.M., Alagebrium reduces glomerular fibrogenesis and inflammation beyond preventing RAGE activation in diabetic apolipoprotein E knockout mice (2012) Diabetes, 61 (8), pp. 2105-2113</label>
          <listPosition>203</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764808</mtid>
          <link>/api/reference/32764808</link>
          <label>204. Wilkinson-Berka, J.L., ALT-946 and aminoguanidine, inhibitors of advanced glycation, improve severe nephropathy in the diabetic transgenic (mREN-2)27 rat (2002) Diabetes, 51 (11), pp. 3283-3289</label>
          <listPosition>204</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764810</mtid>
          <link>/api/reference/32764810</link>
          <label>205. Xiao, Y.D., Thioredoxin-interacting protein mediates NLRP3 inflammasome activation involved in the susceptibility to ischemic acute kidney injury in diabetes (2016) Oxidative Med Cell Longev, 2016</label>
          <listPosition>205</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764811</mtid>
          <link>/api/reference/32764811</link>
          <label>206. Xin, R., Apocynin inhibited NLRP3/XIAP signalling to alleviate renal fibrotic injury in rat diabetic nephropathy (2018) Biomed Pharmacother, 106, pp. 1325-1331</label>
          <listPosition>206</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764812</mtid>
          <link>/api/reference/32764812</link>
          <label>207. Xu, Y., Multiple-modulation effects of oridonin on the production of proinflammatory cytokines and neurotrophic factors in LPS-activated microglia (2009) Int Immunopharmacol, 9 (3), pp. 360-365</label>
          <listPosition>207</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764813</mtid>
          <link>/api/reference/32764813</link>
          <label>208. Yang, S.M., Thrombomodulin domain 1 ameliorates diabetic nephropathy in mice via anti-NF-kappaB/NLRP3 inflammasome-mediated inflammation, enhancement of NRF2 antioxidant activity and inhibition of apoptosis (2014) Diabetologia, 57 (2), pp. 424-434</label>
          <listPosition>208</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764814</mtid>
          <link>/api/reference/32764814</link>
          <label>209. You, Y.H., Role of Nox2 in diabetic kidney disease (2013) Am J Physiol Renal Physiol, 304 (7), pp. F840-F848</label>
          <listPosition>209</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764815</mtid>
          <link>/api/reference/32764815</link>
          <label>210. You, Y.H., Metabolomics reveals a key role for fumarate in mediating the effects of NADPH oxidase 4 in diabetic kidney disease (2016) J am Soc Nephrol, 27 (2), pp. 466-481</label>
          <listPosition>210</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764816</mtid>
          <link>/api/reference/32764816</link>
          <label>211. Zhang, H., Podocyte-specific JAK2 overexpression worsens diabetic kidney disease in mice (2017) Kidney Int, 92 (4), pp. 909-921</label>
          <listPosition>211</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764817</mtid>
          <link>/api/reference/32764817</link>
          <label>212. Zhang, X., Effects of coenzyme Q10 intervention on diabetic kidney disease: A systematic review and meta-analysis (2019) Medicine (Baltimore), 98 (24)</label>
          <listPosition>212</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764818</mtid>
          <link>/api/reference/32764818</link>
          <label>213. Zhang, C., A small molecule inhibitor MCC950 ameliorates kidney injury in diabetic nephropathy by inhibiting NLRP3 inflammasome activation (2019) Diabetes Metab Syndr Obes, 12, pp. 1297-1309</label>
          <listPosition>213</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764819</mtid>
          <link>/api/reference/32764819</link>
          <label>214. Zheng, H., Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy (2011) Diabetes, 60 (11), pp. 3055-3066</label>
          <listPosition>214</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>32764820</mtid>
          <link>/api/reference/32764820</link>
          <label>215. Zoppini, G., Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function (2012) Diabetes Care, 35 (1), pp. 99-104</label>
          <listPosition>215</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
      </references>
      <link>/api/publication/33044489</link>
      <label>Aboolian A. et al. Diabetic Kidney Disease: From Pathogenesis to Novel Treatment Possibilities. (2022) HANDBOOK OF EXPERIMENTAL PHARMACOLOGY 0171-2004 1865-0325 274 269-307</label><template>&lt;div class=&quot;JournalArticle Publication short-list&quot;&gt; &lt;div class=&quot;authors&quot;&gt; &lt;span class=&quot;author-name&quot; &gt; Aboolian, A. &lt;/span&gt; &lt;span class=&quot;author-type&quot;&gt; &lt;/span&gt; ; &lt;span class=&quot;author-name&quot; &gt; Urner, S. &lt;/span&gt; &lt;span class=&quot;author-type&quot;&gt; &lt;/span&gt; ; &lt;span class=&quot;author-name&quot; &gt; Roden, M. &lt;/span&gt; &lt;span class=&quot;author-type&quot;&gt; &lt;/span&gt; ; &lt;span class=&quot;author-name&quot; &gt; Jha, J.C. &lt;/span&gt; &lt;span class=&quot;author-type&quot;&gt; &lt;/span&gt; ; &lt;span class=&quot;author-name&quot; &gt; Jandeleit-Dahm, K. ✉ &lt;/span&gt; &lt;span class=&quot;author-type&quot;&gt; &lt;/span&gt; &lt;/div &gt;&lt;div class=&quot;title&quot;&gt;&lt;a href=&quot;/gui2/?mode=browse&amp;params=publication;33044489&quot; mtid=&quot;33044489&quot; target=&quot;_blank&quot;&gt;Diabetic Kidney Disease: From Pathogenesis to Novel Treatment Possibilities&lt;/a&gt;&lt;/div&gt; &lt;div class=&quot;pub-info&quot;&gt; &lt;span class=&quot;journal-title&quot;&gt;HANDBOOK OF EXPERIMENTAL PHARMACOLOGY&lt;/span&gt; &lt;span class=&quot;journal-volume&quot;&gt;274&lt;/span&gt; &lt;span class=&quot;page&quot;&gt; pp. 269-307. , 39 p. &lt;/span&gt; &lt;span class=&quot;year&quot;&gt;(2022)&lt;/span&gt; &lt;/div&gt; &lt;div class=&quot;pub-end&quot;&gt;&lt;div class=&quot;identifier-list&quot;&gt; &lt;span class=&quot;identifiers&quot;&gt; &lt;span class=&quot;id identifier oa_none&quot; title=&quot;none&quot;&gt; &lt;a style=&quot;color:blue&quot; title=&quot;10.1007/164_2021_576&quot; target=&quot;_blank&quot; href=&quot;https://doi.org/10.1007/164_2021_576&quot;&gt; DOI &lt;/a&gt; &lt;/span&gt; &lt;span class=&quot;id identifier oa_none&quot; title=&quot;none&quot;&gt; &lt;a style=&quot;color:black&quot; title=&quot;001283235100015&quot; target=&quot;_blank&quot; href=&quot;https://www.webofscience.com/wos/woscc/full-record/001283235100015&quot;&gt; WoS &lt;/a&gt; &lt;/span&gt; &lt;span class=&quot;id identifier oa_none&quot; title=&quot;none&quot;&gt; &lt;a style=&quot;color:blue&quot; title=&quot;85134855180&quot; target=&quot;_blank&quot; href=&quot;http://www.scopus.com/record/display.url?origin=inward&amp;eid=2-s2.0-85134855180&quot;&gt; Scopus &lt;/a&gt; &lt;/span&gt; &lt;/span&gt; &lt;/div&gt; &lt;div class=&quot;short-pub-prop-list&quot;&gt; &lt;span class=&quot;short-pub-mtid&quot;&gt; Publication:33044489 &lt;/span&gt; &lt;span class=&quot;status-holder&quot;&gt;&lt;span class=&quot;status-data status-APPROVED&quot;&gt; Published &lt;/span&gt;&lt;/span&gt; &lt;span class=&quot;pub-core&quot;&gt; Citing &lt;/span&gt; &lt;span class=&quot;pub-type&quot;&gt;Journal Article (Article ) &lt;/span&gt; &lt;!-- &amp;&amp; !record.category.scientific --&gt; &lt;span class=&quot;pub-category&quot;&gt;Scientific&lt;/span&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;</template><template2>&lt;div class=&quot;JournalArticle Publication long-list&quot;&gt;
&lt;div class=&quot;authors&quot;&gt;
	
	&lt;img title=&quot;Idézőközlemény&quot; style=&quot;float: left&quot; src=&quot;/frontend/resources/grid/publication-citation-icon.png&quot;&gt;

		&lt;div class=&quot;autype autype0&quot;&gt;				&lt;span class=&quot;author-name&quot; &gt;Aboolian A.
    &lt;/span&gt;
;&amp;nbsp;&amp;nbsp;&amp;nbsp;
							&lt;span class=&quot;author-name&quot; &gt;Urner S.
    &lt;/span&gt;
;&amp;nbsp;&amp;nbsp;&amp;nbsp;
							&lt;span class=&quot;author-name&quot; &gt;Roden M.
    &lt;/span&gt;
;&amp;nbsp;&amp;nbsp;&amp;nbsp;
							&lt;span class=&quot;author-name&quot; &gt;Jha J.C.
    &lt;/span&gt;
;&amp;nbsp;&amp;nbsp;&amp;nbsp;
							&lt;span class=&quot;author-name&quot; &gt;Jandeleit-Dahm K. ✉
    &lt;/span&gt;

				    &lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;title&quot;&gt;&lt;a href=&quot;/gui2/?mode=browse&amp;params=publication;33044489&quot; target=&quot;_blank&quot;&gt;Diabetic Kidney Disease: From Pathogenesis to Novel Treatment Possibilities&lt;/a&gt;&lt;/div&gt;    &lt;div&gt;		&lt;span class=&quot;journal-title&quot;&gt;HANDBOOK OF EXPERIMENTAL PHARMACOLOGY&lt;/span&gt;

        &lt;span class=&quot;journal-issn&quot;&gt;(&lt;a target=&quot;_blank&quot; href=&quot;https://portal.issn.org/resource/ISSN/0171-2004&quot;&gt;0171-2004&lt;/a&gt; &lt;a target=&quot;_blank&quot; href=&quot;https://portal.issn.org/resource/ISSN/1865-0325&quot;&gt;1865-0325&lt;/a&gt;)&lt;/span&gt;:
		&lt;span class=&quot;journal-volume&quot;&gt;274&lt;/span&gt; 
&lt;span class=&quot;page&quot;&gt;
	pp 269-307
			
&lt;/span&gt;		 &lt;span class=&quot;year&quot;&gt;(2022)&lt;/span&gt;  
    &lt;/div&gt;
&lt;div class=&quot;pub-footer&quot;&gt;

	&lt;span class=&quot;language&quot; xmlns=&quot;http://www.w3.org/1999/html&quot;&gt;Language:
			English
		 |  &lt;/span&gt;

	&lt;span class=&quot;identifiers&quot;&gt;
						&lt;span class=&quot;id identifier oa_none&quot; title=&quot;none&quot;&gt;
							
							&lt;a style=&quot;color:blue&quot; title=&quot;10.1007/164_2021_576&quot; target=&quot;_blank&quot; href=&quot;https://doi.org/10.1007/164_2021_576&quot;&gt;
									DOI
							&lt;/a&gt;
						&lt;/span&gt;
						&lt;span class=&quot;id identifier oa_none&quot; title=&quot;none&quot;&gt;
							
							&lt;a style=&quot;color:black&quot; title=&quot;001283235100015&quot; target=&quot;_blank&quot; href=&quot;https://www.webofscience.com/wos/woscc/full-record/001283235100015&quot;&gt;
									WoS
							&lt;/a&gt;
						&lt;/span&gt;
						&lt;span class=&quot;id identifier oa_none&quot; title=&quot;none&quot;&gt;
							
							&lt;a style=&quot;color:blue&quot; title=&quot;85134855180&quot; target=&quot;_blank&quot; href=&quot;http://www.scopus.com/record/display.url?origin=inward&amp;eid=2-s2.0-85134855180&quot;&gt;
									Scopus
							&lt;/a&gt;
						&lt;/span&gt;
	&lt;/span&gt;




	&lt;div class=&quot;publication-citation&quot;&gt;
		&lt;a target=&quot;_blank&quot; href=&quot;/api/publication?cond=citations.related;eq;33044489&amp;sort=publishedYear,desc&amp;sort=title&quot;&gt;
			Number of cited publications: 8
		&lt;/a&gt;
	&lt;/div&gt;



    &lt;div class=&quot;mtid&quot;&gt;&lt;span class=&quot;long-pub-mtid&quot;&gt;Publication: 33044489&lt;/span&gt;
    | &lt;span class=&quot;status-data status-APPROVED&quot;&gt; 	Published
  &lt;/span&gt;
        
	
	
	 Citing
	
	
    | &lt;span class=&quot;type-subtype&quot;&gt;Journal Article
			( Article
			
			)
		&lt;/span&gt;
      		| &lt;span class=&quot;pub-category&quot;&gt;Scientific&lt;/span&gt;
	| &lt;span class=&quot;publication-sourceOfData&quot;&gt;Scopus&lt;/span&gt;
&lt;/div&gt;


&lt;div class=&quot;lastModified&quot;&gt;Last Modified: 2024.12.12. 13:51 Zóra Kondor (SE_KK_Admin5_KZ, admin)
&lt;/div&gt;




	&lt;pre class=&quot;comment&quot; style=&quot;margin-top: 0; margin-bottom: 0;&quot;&gt;&lt;u&gt;Comments&lt;/u&gt;: Institute for Clinical Diabetology, German Diabetes Centre, Leibniz Centre for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, Germany            
            Department of Endocrinology and Diabetology, Medical Faculty, University Hospital Düsseldorf, Düsseldorf, Germany            
            German Centre for Diabetes Research, Partner Düsseldorf, München-Neuherberg, ...&lt;/pre&gt;

&lt;/div&gt;&lt;/div&gt;</template2>
    </publication>
  </content>
</myciteResult>
